Available EXPANDED_ACCESS NCT04745637

Managed Access Programs for INC424, Ruxolitinib

Sponsor: Novartis Pharmaceuticals

Conditions Polycythemia Vera (PV) Post Polycythemia Myelofibrosis (PPV MF) Primary Myelofibrosis (PMF) Severe/Very Severe COVID-19 Illness Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD) Steroid Refractory Chronic Graft Versus Host Disease (SR cGVHD) Thrombocythemia Myelofibrosis (PET-MF)

Interventions Ruxolitinib

Updated 11 times since 2021 Last updated: Nov 14, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Polycythemia Vera (PV) and Post Polycythemia Myelofibrosis (PPV MF) and is currently ongoing. Novartis Pharmaceuticals leads this study, which shows 11 recorded versions since 2026 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

11 versions recorded

Dec 2025 — Present [monthly]

Available
Feb 2025 — Dec 2025 [monthly]

Available
Nov 2024 — Feb 2025 [monthly]

Available
Oct 2024 — Nov 2024 [monthly]

Available
Sep 2024 — Oct 2024 [monthly]

Available

▶ Show 6 earlier versions

Jul 2024 — Sep 2024 [monthly]

Available
Mar 2024 — Jul 2024 [monthly]

Available
Dec 2023 — Mar 2024 [monthly]

Available
Feb 2023 — Dec 2023 [monthly]

Available
Feb 2022 — Feb 2023 [monthly]

Available
Mar 2021 — Feb 2022 [monthly]

Available

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.